GE to Invest $80 Million to Expand Contrast Media Production Capacity
GE Healthcare ’s Pharmaceutical Diagnostics will be investing $80 million at its Active Pharmaceutical Ingredients (API) site in Lindesnes, Norway, to expand iodinated contrast media production capacity. The company says its part of a broader commitment to address significant future global demand for iodinated contrast media, used in Xray and Computed Tomography (CT) procedures around the world to enhance visualization of organs, blood vessels and tissues across disease pathways. The investment will also create 100 new jobs.
Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second. This new investment, coupled with the recent opening of a new production line at GE Healthcare’s Cork, Ireland, fill and finish facility, aims to enable the production of 30 million more patient doses per year by 2025.
President & CEO of GE Healthcare Pharmaceutical Diagnostics, Kevin O’Neill, said, “We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures. This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe.”
The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API. All stages of its contrast media manufacturing, from development of Active Pharmaceutical Ingredient (API) to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices.
Recently, GE Healthcare announced a multi-year agreement with SQM, a Chile-based mining company, to secure increasing supply of iodine, the key ingredient in iodinated contrast media.